Finasteride and Alcohol Interaction Profile: What You Need to Know

How Finasteride Works and Why Alcohol Becomes Relevant

Finasteride is a selective, irreversible inhibitor of 5-alpha-reductase type II (and, at the 5 mg dose, also type I), the enzyme that converts testosterone to dihydrotestosterone (DHT). The FDA approved 1 mg (Propecia) for androgenetic alopecia in 1997 and 5 mg (Proscar) for benign prostatic hyperplasia in 1992. [1]

The Drug's Metabolic Pathway

Finasteride is metabolized primarily in the liver by cytochrome P450 3A4 (CYP3A4), with two inactive carboxylic acid and omega-hydroxy metabolites excreted in bile and urine. The elimination half-life is roughly six hours in younger men and up to eight hours in men over 70. [1]

Alcohol metabolism, by contrast, relies on alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), and at higher concentrations also on the microsomal ethanol-oxidizing system (MEOS), which overlaps with the CYP2E1 and, to a lesser degree, CYP3A4 pathways. [2] That pathway overlap is why chronic heavy drinking can theoretically alter finasteride clearance, even though a dedicated pharmacokinetic interaction study has not been published.

What the FDA Label Does and Does Not Say

The current finasteride prescribing information does not list alcohol as a named drug interaction. The label notes that finasteride is a CYP3A4 substrate and that no clinically significant interactions have been identified with drugs that inhibit or induce CYP3A4 at therapeutic concentrations. [1] Absence from the label is reassuring for moderate drinkers, but it should not be read as clearance for chronic heavy use.

Hepatic Considerations: Overlapping Stress on the Liver

Both finasteride and alcohol demand hepatic processing. For most patients this is a non-issue, but the overlap becomes clinically meaningful in two groups: people who drink heavily (more than 14 units per week) and people who have pre-existing liver disease.

Finasteride's Hepatotoxicity Signal

Post-marketing surveillance has identified rare cases of drug-induced liver injury (DILI) associated with finasteride. A 2016 systematic review of 5-alpha-reductase inhibitor safety published in the European Journal of Internal Medicine noted transaminase elevations in a small subset of BPH trial participants, though severe hepatotoxicity remains rare. [3] The FDA adverse event reporting system (FAERS) contains case reports of cholestatic hepatitis attributed to finasteride, though causality is difficult to confirm from spontaneous reports alone.

Alcohol's Liver Burden

Chronic alcohol use causes a spectrum of liver disease ranging from steatosis to fibrotic cirrhosis. Even moderate drinking raises alanine aminotransferase (ALT) by an average of 15 to 25% in susceptible individuals. [4] When a liver is already under alcoholic stress, adding any hepatically metabolized drug increases the risk of transaminase elevation and, at the extreme end, acute-on-chronic liver failure.

Practical Monitoring Threshold

For patients with no known liver disease who drink fewer than 14 units per week, no additional liver monitoring beyond standard of care is typically warranted. For patients who drink more than that, a baseline comprehensive metabolic panel (CMP) before starting finasteride, and a repeat CMP at three months, is a reasonable clinical precaution. This is not yet codified in a named guideline, but it aligns with general DILI-risk-minimization principles from the NIH LiverTox database. [5]

Sexual Side Effects: Why Alcohol Makes This More Complicated

The most discussed adverse effects of finasteride are sexual: reduced libido, erectile dysfunction (ED), and ejaculatory dysfunction. The PLESS trial (N=3,040), the key 4-year BPH study, reported ED in 8.1% of the finasteride 5 mg group vs. 3.7% placebo (P<0.001). [6] For the 1 mg dose in hair-loss trials, ED incidence was approximately 1.3% vs. 0.7% placebo.

Alcohol's Independent Effect on Sexual Function

Alcohol is an independent cause of sexual dysfunction. Ethanol reduces testosterone by suppressing the hypothalamic-pituitary-gonadal (HPG) axis. A study in Clinical Endocrinology (N=66 healthy men) found that acute alcohol ingestion at 0.6 g/kg reduced serum testosterone by an average of 6.8% within 90 minutes. [7] Chronic heavy drinking is associated with sustained hypogonadism, Leydig cell dysfunction, and reduced libido independent of any medication.

The Additive Risk Problem

When a drug that lowers DHT (finasteride) combines with a substance that lowers testosterone (alcohol), the two mechanisms converge on the same target: the androgen signaling that supports libido and erectile function. The result is not a pharmacokinetic interaction in the strict sense; it is a pharmacodynamic overlap, where two separate agents produce the same downstream endpoint through different mechanisms.

This additive risk is particularly relevant for patients who already report borderline sexual side effects on finasteride and then increase their alcohol intake. Clinicians should ask about drinking habits when a patient on stable finasteride reports new or worsening sexual dysfunction.

Post-Finasteride Syndrome Context

Post-finasteride syndrome (PFS) is a controversial but documented cluster of persistent sexual, neurological, and psychological symptoms that some men report after stopping finasteride. The National Institutes of Health recognizes PFS as a condition under active research. [8] Alcohol's own effects on neurosteroid metabolism (including allopregnanolone, which is a downstream product of the same 5-alpha-reductase pathway finasteride blocks) mean that heavy drinkers may have a theoretically altered baseline neurosteroid environment before they even take the drug. Whether this changes PFS risk is unknown; no controlled trial has addressed it.

Mood, Anxiety, and Depression: A Shared Vulnerability

Finasteride has a small but documented signal for depressive symptoms. A 2020 JAMA Dermatology cohort study (N=79,968 men 16 to 42 years old) found that men prescribed finasteride had a 1.94-fold higher odds of depression diagnosis within 1.5 years of starting the drug vs. Unexposed controls. [9]

Alcohol as a CNS Depressant

Alcohol is a central nervous system depressant that acutely boosts GABA and suppresses glutamate. Regular heavy use is independently associated with major depressive disorder; a 2019 Lancet Psychiatry Mendelian randomization study (N>400,000) found a causal relationship between alcohol consumption and depression risk. [10]

What the Combined Risk Looks Like Clinically

A patient taking finasteride who also drinks heavily is exposed to two independent depression-risk factors. Neither the finasteride label nor any published guideline has quantified the combined risk, but the directional signal from both literatures is the same. Prescribers should screen for depressive symptoms at follow-up visits for patients on finasteride who use alcohol regularly, using a validated tool such as the PHQ-9.

HealthRX Clinical Decision Framework: Finasteride + Alcohol Risk Stratification

| Drinking Pattern | Weekly Units | Recommended Action | |---|---|---| | Non-drinker or rare drinker | 0 to 2 | No additional monitoring; standard finasteride follow-up | | Moderate drinker | 3 to 14 | Baseline LFTs if not done in prior 12 months; PHQ-9 at 3-month follow-up | | Heavy drinker | 15 to 28 | Baseline and 3-month CMP plus PHQ-9; discuss risk-benefit with prescriber before starting | | Very heavy or daily drinker | >28 | Evaluate and treat alcohol use disorder before initiating finasteride; consider hepatology co-management |

Units defined per UK NHS standard (1 unit = 8 g ethanol). US standard drinks (14 g ethanol) are approximately 1.75 UK units.

Pharmacokinetic Interaction: What We Actually Know (and What We Don't)

No dedicated pharmacokinetic drug-drug interaction study between finasteride and alcohol appears in PubMed as of July 2025. The absence of published data is common for alcohol-drug pairs because ethanol is rarely included in formal Phase I interaction studies.

CYP3A4 Induction at High Alcohol Intake

Chronic heavy alcohol intake upregulates CYP2E1 significantly and induces CYP3A4 modestly via activation of the pregnane X receptor (PXR). [2] If CYP3A4 activity increases meaningfully in a heavy drinker, finasteride could theoretically be cleared faster, leading to slightly lower steady-state plasma concentrations. The clinical significance of this effect for a drug like finasteride, which works through deep tissue DHT suppression rather than a tight plasma concentration-response relationship, is probably minimal but has not been tested.

Protein Binding

Finasteride is approximately 90% plasma protein-bound. Acute alcohol intoxication has not been shown to meaningfully displace protein-bound drugs in humans at typical drinking concentrations, so displacement interactions are not a concern here.

Half-Life and Timing

Because finasteride's half-life is six to eight hours and it is taken daily, the pharmacokinetic exposure profile is fairly stable. A single evening of moderate drinking is unlikely to produce a measurable change in finasteride exposure on the following morning. This is reassuring for patients who want to know whether a social drink will affect their medication's efficacy for hair loss or BPH.

Special Populations: Who Needs More Caution

Men Over 60 on 5 mg Finasteride

Older men are the primary BPH population. Hepatic metabolic capacity declines with age, and alcohol tolerance also decreases due to reduced hepatic volume and lower total body water. The combination of age-related pharmacokinetic changes plus finasteride's longer half-life in this group (up to eight hours) plus any alcohol-related liver stress makes a lower threshold for monitoring appropriate. The American Urological Association (AUA) 2021 BPH guideline does not address alcohol directly, but its general recommendation to monitor for adverse effects at each follow-up visit applies here. [11]

Men With HIV or on Antiretrovirals

Several antiretroviral drugs, particularly ritonavir and cobicistat, are potent CYP3A4 inhibitors. When an HIV-positive man on a ritonavir-boosted regimen also drinks heavily, two separate modifiers of CYP3A4 activity are present alongside finasteride. This scenario warrants a formal pharmacist review of the complete medication list.

Men Using Anabolic Steroids or Exogenous Testosterone

Some men use finasteride specifically to block DHT conversion from exogenous testosterone during TRT or anabolic steroid cycles. Alcohol in this context adds a third androgen-pathway variable, compounding the difficulty of predicting net androgenic or sexual function outcomes.

Practical Guidance for Patients

How to Time Drinks Around Your Dose

Finasteride is typically taken once daily, and timing relative to alcohol is not clinically validated. Given the six-hour half-life, peak plasma exposure occurs in the first two hours after the dose. Spacing alcohol consumption at least two to three hours from the dose is a low-cost precaution with no supporting trial data but a reasonable pharmacokinetic rationale.

Signs That You Should Contact Your Prescriber

Contact your provider if, while combining finasteride with regular alcohol use, you notice:

• Jaundice, right upper quadrant pain, or dark urine (possible liver injury)
• A meaningful new decline in libido or erections not explained by other factors
• Persistent low mood, tearfulness, or loss of interest in usual activities (PHQ-9 score above 5)
• Breast tenderness or nipple discharge (gynecomastia, which alcohol can worsen by increasing aromatase activity)

The Gynecomastia Connection

Both alcohol and finasteride can alter the testosterone-to-estrogen ratio. Finasteride reduces DHT but does not directly change estrogen. Alcohol increases aromatase activity, shifting testosterone toward estradiol. In combination, the result can be a relatively higher estrogen environment, which may increase gynecomastia risk. A small case series published in Endocrine Practice described three men who developed gynecomastia while on finasteride; all three were also regular drinkers, though causality was not established. [12]

What Prescribers Should Document

Prescribers initiating finasteride should record:

1. Baseline alcohol use in standard drinks or units per week, using a validated screen such as the AUDIT-C.
2. Baseline LFTs (ALT, AST, total bilirubin) for any patient drinking more than 14 units per week.
3. PHQ-9 or equivalent depression screen at baseline and the first follow-up visit.
4. Explicit documentation that the patient was counseled on alcohol's additive sexual dysfunction and mood risk.

The 2021 American Urological Association guideline on male lower urinary tract symptoms states: "Patients should be counseled regarding the potential for sexual side effects of 5-ARI therapy, and these discussions should be documented." [11] Alcohol's role in amplifying those side effects falls within the spirit of that recommendation.